Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Accounts Payables (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Accounts Payables data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 9.28% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, up 9.28%, while the annual FY2025 figure was $2.1 million, 9.28% up from the prior year.
  • Accounts Payables reached $2.1 million in Q4 2025 per VRCA's latest filing, up from $1.6 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.5 million in Q1 2024 and bottomed at $137000.0 in Q3 2022.
  • Average Accounts Payables over 5 years is $1.3 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: tumbled 84.85% in 2022, then skyrocketed 1305.11% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $845000.0 in 2021, then plummeted by 40.0% to $507000.0 in 2022, then surged by 386.0% to $2.5 million in 2023, then fell by 23.05% to $1.9 million in 2024, then rose by 9.28% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $2.1 million in Q4 2025, $1.6 million in Q3 2025, and $2.3 million in Q2 2025.